Athira cited altered research in $15 million NIH grant application

Table of Contents1 What is it?2 What is integrated? Biotech business Athira Pharma, which is

Biotech business Athira Pharma, which is in turmoil immediately after its main executive was identified to have revealed investigation containing altered photographs, now faces a new issue: It cited the allegedly doctored papers in a federal grant software. This results in the likely for the governing administration or whistleblowers to go after lawful action to pressure the company to repay not only the $15 million it obtained to fund its function but also additional penalties.

Three altered papers co-authored by previous chief executive Leen Kawas — who has been positioned on depart — were being referenced in an Athira application for funding from the Nationwide Institutes of Well being, which STAT received through a Liberty of Info Act ask for. This tends to make the Seattle-centered company likely liable for Fake Claims Act damages, in accordance to two lawful specialists, that means Athira could be on the hook for three occasions the grant resources, or $45 million.

Unlock this posting by subscribing to STAT+ and take pleasure in your initially 30 times free!

GET Started

What is it?

STAT+ is STAT’s high quality membership service for in-depth biotech, pharma, coverage, and lifetime science coverage and investigation.
Our award-profitable team covers news on Wall Road, coverage developments in Washington, early science breakthroughs and medical trial success, and health treatment disruption in Silicon Valley and further than.

What is integrated?

  • Each day reporting and investigation
  • The most detailed industry protection from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most vital industry news of the day
  • STAT+ Discussions
  • Weekly possibilities to interact with our reporters and major field gurus in stay online video discussions
  • Exceptional sector functions
  • Top quality accessibility to subscriber-only networking events around the nation
  • The ideal reporters in the field
  • The most reliable and properly-related newsroom in the health treatment sector
  • And substantially more
  • Unique interviews with field leaders, profiles, and quality equipment, like our CRISPR Trackr.
Exit mobile version